The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Abstract
Purpose: The National Surgical Adjuvant Breast and Bowel Project Protocol B-27 was designed to determine the effect of adding docetaxel after four cycles of preoperative doxorubicin and cyclophosphamide (AC) on clinical and pathological response rates and on disease-free and overall survival of women with operable breast cancer. Patients and Methods: Women (N = 2,411) with operable primary breast cancer were randomly assigned to receive either four cycles of preoperative AC followed by surgery (group I), or four cycles of AC followed by four cycles of docetaxel, followed by surgery (group II), or four cycles of AC followed by surgery and then four cycles of docetaxel (group III). Clinical and pathologic tumor responses to preoperative therapy were assessed. Results: Mean tumor size (4.5 cm) and other key characteristics were evenly balanced among the three treatment arms. Grade 4 toxicity was observed in 10.3% of 2,400 patients during AC treatment, and in 23.4% of 1584 patients during docetaxel treatment. Compared to preoperative AC alone, preoperative AC followed by docetaxel increased the clinical complete response rate (40.1% v 63.6%; P < .001), the overall clinical response rate (85.5% v 90.7%; P < .001), the pathologic complete response rate (13.7% v 26.1%; P < .001), and the proportion of patients with negative nodes (50.8% v 58.2%; P < .001). Pathologic primary breast tumor response was a significant predictor of pathologic nodal status (P < .001). Conclusion: The addition of four cycles of preoperative docetaxel after four cycles of preoperative AC significantly increased clinical and pathologic response rates for operable breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Self-citationPolychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
van der Hage, J. A., van de Velde, C. J. H., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., & Cooperating Investigators (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4224 · Cited by 1,107
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Moliterni, A., Terenziani, M., & Zambetti, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.93 · Cited by 566
Hortobagyi, G. N., Ames, F. C., Buzdar, A. U., Kau, S. W., McNeese, M. D., Paulus, D., Hug, V., Holmes, F. A., Romsdahl, M. M., Fraschini, G., et al. (1988) · Cancer · doi:10.1002/1097-0142(19881215)62:12<2507::aid-cncr2820621210>3.0.co;2-d · Cited by 504
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery, M.-C., Guénard, D., Guéritte, F., & Lavelle, F. (1991) · PubMed · Cited by 481
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Scholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangié, T., Jouve, M., Beuzeboc, P., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90537-1 · Cited by 424
Cortes, J. E., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2643 · Cited by 421
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Ravdin, P. M., Burris, H. A., Cook, G., Eisenberg, P., Kane, M., Bierman, W. A., Mortimer, J., Genevois, E., & Bellet, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 317
Rouzier, R., Extra, J.-M., Klijanienko, J., Falcou, M.-C., Asselain, B. J. R., Vincent‐Salomon, A., Vielh, P. R., & Bourstyn, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1304 · Cited by 315
Mauriac, L., Durand, M., Avril, A., & Dilhuydy, J.-M. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057953 · Cited by 268
Buzdar, A. U., Singletary, S. E., Theriault, R. L., Booser, D. J., Valero, V., Ibrahim, N., Smith, T. L., Asmar, L., Frye, D., Manuel, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3412 · Cited by 242
Reichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Kinetics of mammary tumor cell growth and implications for therapy
Skipper, H. E. (1971) · Cancer · doi:10.1002/1097-0142(197112)28:6<1479::aid-cncr2820280622>3.0.co;2-m · Cited by 234
Wilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., & O'Shaughnessy, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1621 · Cited by 216
Seidman, A. D., Reichman, B. S., Crown, J. P., Yao, T. J., Currie, V, Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., & Forsythe, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1152 · Cited by 205
Seidman, A. D., Tiersten, A., Hudis, C., Gollub, M., Barrett, S., Yao, T. J., Lepore, J., Gilewski, T., Currie, V, & Crown, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 203
Perloff, M., Lesnick, G. J., Korzun, A., Chu, F., Holland, J. F., Thirlwell, M. P., Ellison, R. R., Carey, R. W., Leone, L., & Weinberg, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.261 · Cited by 195
Lena, M. D., Varini, M., Zucali, R., Rovini, D., Viganotti, G., Valagussa, P., Veronesi, U., & Bonadonna, G. (1981) · PubMed · Cited by 155
Scholl, S., Pierga, J., Asselain, B. J. R., Beuzeboc, P., Dorval, T., García-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J. C., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00454-8 · Cited by 152
Machiavelli, M. R., Romero, A. O., Pérez, J. E., Lacava, J. A., Domínguez, M. E., Rodriguez, R. J., Barbieri, M. R., Acuña, L. A. R., Acuña, J. M. R., Langhi, M. J., et al. (1998) · PubMed · Cited by 144
von Minckwitz, G., Costa, S. D., Raab, G., Blohmer, J., Eidtmann, H., Hilfrich, J., Merkle, E., Jackisch, C., Gademann, G., Tulusan, A. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3506 · Cited by 144
Gianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A. T., Martini, C., Laffranchi, A., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1169 · Cited by 144
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer
Ibrahim, N. K., Şahin, A. A., DuBrow, R. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06195-4 · Cited by 141
Comprehensive management of locally advanced breast cancer
Hortobágyi, G. N. (1990) · Cancer · Cited by 133
Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A. G., Namer, M., Schraub, S., Goudier, M.-J., Mihura, J., Monnier, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.148 · Cited by 105
Primary Chemotherapy in Breast Cancer
Ferrière, J.-P., Assier, I., Curé, H., Charrier, S., Kwiatkowski, F., Achard, J. L., Dauplat, J., & Chollet, P. J. M. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199804000-00003 · Cited by 69
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
Fountzilas, G., Athanassiades, A., Giannakakis, T., Bafaloukos, D. I., Karakousis, K., Dombros, N., Kosmidis, P., & Skarlos, D. V. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00398-3 · Cited by 53
Taxanes in the Treatment of Breast Cancer: A Prodigy Comes of Age
Miller, K. D., & Sledge, G. W. (1999) · Cancer Investigation · doi:10.1080/07357909909011727 · Cited by 44
Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy.
Giap, H., Macey, D. J., & Podoloff, D. A. (1995) · PubMed · Cited by 40
Taxanes in the Adjuvant Treatment of Breast Cancer: Why Not Yet?
Piccart, M. J., Lohrisch, C. A., Duchateau, L., & Buyse, M. E. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003468 · Cited by 37
Archer, C. D., Lowdell, C. P., Sinnett, H. D., English, J., Khan, S., & Coombes, R. C. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10113-7 · Cited by 19
Cited by
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Self-citationNeoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Metadata
- Authors
- Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-15
- Volume
- 21
- Issue
- 22
- Pages
- 4165-4174
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162760540
- Cited by
- 1,118
- References
- 42
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.